期刊
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
卷 40, 期 6, 页码 792-803出版社
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0039-1697975
关键词
FEV (1); respiratory symptoms; pulmonary exacerbation; cystic fibrosis; treatment duration
资金
- Cystic Fibrosis Foundation Therapeutics [GOSS13A0]
- NIH [P30 DK089507, UL1TR000423]
With the improving survival of cystic fibrosis (CF) patients and the advent of highly effective cystic fibrosis transmembrane conductance regulator therapy, the clinical spectrum of this complex multisystem disease continues to evolve. One of the most important clinical events for patients with CF in the course of this disease is an acute pulmonary exacerbation. Clinical and microbial epidemiology studies of CF pulmonary exacerbations continue to provide important insight into the disease course, prognosis, and complications. This work has now led to a number of large scale clinical trials with the goal of improving the treatment paradigm for CF pulmonary exacerbation. The primary goal of this review is to provide a summary of the pathophysiology, the clinical epidemiology, microbial epidemiology, outcome and the treatment of CF pulmonary exacerbation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据